• Vivani Medical entered an agreement with Novo Nordisk to let Novo evaluate NPM-139, its miniature ultra long-acting semaglutide implant for chronic weight management.
• The agreement includes no exclusivity for NPM-139 or Vivani’s NanoPortal implant technology.
• Vivani plans a Phase 1 first-in-human trial in mid-2026, comparing NPM-139 with Wegovy injections to assess safety, pharmacokinetics, tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070735PRIMZONEFULLFEED9758110) on July 07, 2026, and is solely responsible for the information contained therein.